Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexate
Crossref DOI link:
Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY
John, Markus R.
Choy, Ernest H.
Funding for this research was provided by:
F. Hoffmann-La Roche Ltd.
Text and Data Mining valid from 2018-06-07
27 March 2018
30 May 2018
7 June 2018